Abstract
CD30 ligand (CD30L) and its receptor CD30 are members of the tumor necrosis factor (TNF) and TNF receptor superfamilies that play a major role in inflammation and immune regulation. To gain insight into the in vivo role of CD30L/CD30 in inflammatory diseases, we have used carrageenan (CAR)-induced pleurisy in mice, a preclinical model of airway inflammation where type 1 proinflammatory cytokines such as interleukin (IL)-1 and TNF-alpha play a key pathogenic role. The data show that prophylactic treatment with anti-CD30L mAb markedly reduces both laboratory and histological signs of CAR-induced pleurisy. These data suggest involvement of CD30-mediated signals in acute immunoinflammatory pathways induced by CAR.
MeSH terms
-
Adjuvants, Immunologic / pharmacology*
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / pharmacology*
-
CD30 Ligand
-
Carrageenan / adverse effects
-
Intercellular Adhesion Molecule-1 / metabolism
-
Ki-1 Antigen / immunology
-
Lung / immunology
-
Lung / metabolism
-
Lung / pathology
-
Male
-
Membrane Glycoproteins / immunology*
-
Mice
-
P-Selectin / metabolism
-
Pleurisy / chemically induced
-
Pleurisy / immunology
-
Pleurisy / metabolism
-
Pleurisy / prevention & control*
-
Tumor Necrosis Factor-alpha / metabolism
-
Tyrosine / analogs & derivatives*
-
Tyrosine / metabolism
Substances
-
Adjuvants, Immunologic
-
Antibodies, Monoclonal
-
CD30 Ligand
-
Ki-1 Antigen
-
Membrane Glycoproteins
-
P-Selectin
-
Tnfsf8 protein, mouse
-
Tumor Necrosis Factor-alpha
-
Intercellular Adhesion Molecule-1
-
3-nitrotyrosine
-
Tyrosine
-
Carrageenan